Company news

HUTCHMED (China) Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

October 28, 2026

VOLUNTARY ANNOUNCEMENT - Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

October 26, 2026

VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

October 26, 2026

VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

October 25, 2026

VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

October 20, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended September 30, 2026

October 2, 2026

VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO in MET Driven EGFR-Mutated Lung Cancer

September 28, 2026

VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

September 27, 2026

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

September 27, 2026

VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

September 23, 2026

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

September 2, 2026

HUTCHMED Reports 2026 Interim Results

July 30, 2026

HUTCHMED to Announce 2026 Half-Year Financial Results

June 30, 2026

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

May 21, 2026

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

April 29, 2026

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.